GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Tiantan Biological Products Corp Ltd (SHSE:600161) » Definitions » EBIT

Beijing Tiantan Biological Products (SHSE:600161) EBIT : ¥2,085 Mil (TTM As of Sep. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Beijing Tiantan Biological Products EBIT?

Beijing Tiantan Biological Products's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥535 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥2,085 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Beijing Tiantan Biological Products's annualized ROC % for the quarter that ended in Sep. 2024 was 18.21%. Beijing Tiantan Biological Products's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 30.74%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Beijing Tiantan Biological Products's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 5.33%.


Beijing Tiantan Biological Products EBIT Historical Data

The historical data trend for Beijing Tiantan Biological Products's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Tiantan Biological Products EBIT Chart

Beijing Tiantan Biological Products Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,043.45 1,107.86 1,244.11 1,428.68 1,802.25

Beijing Tiantan Biological Products Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 507.38 357.16 517.42 675.50 535.33

Competitive Comparison of Beijing Tiantan Biological Products's EBIT

For the Biotechnology subindustry, Beijing Tiantan Biological Products's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Tiantan Biological Products's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Tiantan Biological Products's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Beijing Tiantan Biological Products's EV-to-EBIT falls into.


;
;

Beijing Tiantan Biological Products EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,085 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Tiantan Biological Products  (SHSE:600161) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Beijing Tiantan Biological Products's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=2074.64 * ( 1 - 17.25% )/( (9213.734 + 9644.974)/ 2 )
=1716.7646/9429.354
=18.21 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=15139.378 - 1052.138 - ( 4873.506 - max(0, 1575.534 - 8229.179+4873.506))
=9213.734

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=15553.621 - 1103.779 - ( 4804.868 - max(0, 1551.378 - 8542.147+4804.868))
=9644.974

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Beijing Tiantan Biological Products's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2141.312/( ( (5124.898 + max(1642.502, 0)) + (5223.013 + max(1939.844, 0)) )/ 2 )
=2141.312/( ( 6767.4 + 7162.857 )/ 2 )
=2141.312/6965.1285
=30.74 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(21.067 + 3138.286 + 44.83) - (1052.138 + 0 + 509.543)
=1642.502

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(25.427 + 3408.196 + 46.358) - (1103.779 + 0 + 436.358)
=1939.844

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Beijing Tiantan Biological Products's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=2085.401/39096.478
=5.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Tiantan Biological Products EBIT Related Terms

Thank you for viewing the detailed overview of Beijing Tiantan Biological Products's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Tiantan Biological Products Business Description

Traded in Other Exchanges
N/A
Address
No. 6, Boxing 2nd Road, Room 521, Building 8, Beijing Economic and Technological Development Zone, Beijing, CHN, 100024
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business.
Executives
Zhang Yi senior management
Ci Xiang senior management
Fu Dao Xing Directors, senior managers
Hu Li Gang Director
Yang Hui Chuan Director
Liu Ya Na Directors, senior managers
He Yan Lin Directors, senior managers
Wang Jian Ming Supervisors
Wu Zhen Shan senior management

Beijing Tiantan Biological Products Headlines

No Headlines